A new animal study has revealed that the drug rapamycin, approved for use about 15 years ago, might help in the process of slow aging.
The drug was earlier used as an antibiotic and immunosuppressant has drawn extensive interest for its apparent ability to emulate the ability of dietary restriction in helping animals to live both longer and healthier, which could eventually help humans.
However, this medication has some drawbacks, including an increase in insulin resistance that could set the stage for diabetes but the new findings also suggest that the combination of rapamycin and another drug to offset that increase in insulin resistance might provide the benefits of this medication without the unwanted side effect.
Viviana Perez, PhD said that it could provide a way not only to increase lifespan but to address some age-related diseases as well as improve general health and they might find a way for people to not only live longer but to live better and with a higher quality of life.
The researchers suggested that if the research proves correct then the combined use of metformin and rapamycin for treating aging and age-associated diseases in humans might be possible.
The study is published in The Journals of Gerontology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
